Lifeline Scientific, Inc Trading Update (0643F)
2015年2月17日 - 4:00PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMLSIC
RNS Number : 0643F
Lifeline Scientific, Inc
17 February 2015
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Trading Update
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, provides the following trading update for the year ended
31 December 2014.
Lifeline had another successful second half of the year
indicated by growing market adoption and continued positive
clinical evidence reported in support of the Company's lead
products,. The Company saw strong performance within North America
as well as further significant orders from China for its flagship
LifePort(R) Kidney Transporter and related portfolio of
products.
The Company expects to report full year revenues ahead of market
expectations with total revenues for the period up 6% to US$35.2m
(2013: US$33.2m). A key measure of the Company's growth, the sale
of proprietary single-use consumables associated with the LifePort
Kidney Transporter, improved by 12% compared to last year (2013:
US$18.4m).
While substantial investments in international market expansion
and product line extensions continued during 2014, the Company saw
operating profit, adjusted for non-recurring items, improve
significantly from the US$0.9m recorded last year. As a result,
2014 Operating Profit, adjusted for non-recurring items, will also
be ahead of market expectations and therefore above US$2.2m.
The cash position of the Company remains strong, with cash
balances as at 31 December 2014 in line with levels recorded in the
previous year (31 December 2013: US$3.0m).
David Kravitz, CEO of Lifeline Scientific, commented:
"We are very encouraged by the continued growth of LifePort
adoption and use, especially within our established North American
market, and that sales have continued to grow in China, where our
products are being sold under clinical research protocols while
awaiting full Chinese regulatory clearances. The very recent
regulatory approval in China for our market leading preservation
solutions is a positive sign that regulatory approval for our
LifePort Kidney Transporter and it's suite of related single-use
consumables could soon follow. We are also pleased to see growing
clinical evidence that LifePort is improving patient outcomes and
lowering overall costs in renal transplantation. Whilst progress in
Brazil has been slower than expected, clinician demand and clinical
outcome success in key Brazilian transplant centers is strong and
we expect to see a significant pick-up in 2015. Despite these
delays we are grateful to be able to report overall Company results
ahead of expectations. I look forward to providing a more detailed
review of the business in our full year results statement."
The Company will announce results for the year ended 31 December
2014 on Monday 27 April 2015.
For further information:
Lifeline Scientific, Inc. www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Limited Tel: +44 (0)20 7886 2500
Freddy Crossley (Corporate Finance)
Maisie Atkinson (Corporate Broking)
Walbrook Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of kidneys. Employed by surgeons in over
185 leading transplant programmes in 27 countries, LifePorts have
successfully preserved over 47,000 kidneys indicated for clinical
transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modeled upon the clinically proven
technology platform of LifePort Kidney Transporter and the
Company's early HMP prototype successfully used in clinical
transplant studies by surgeons at New York-Presbyterian
Hospital/Columbia University Medical Center. LifePort Liver
Transporter and the Company's proprietary machine preservation
solution, Vasosol(R), are in the process of US and European
regulatory registrations. The system is designed to help improve
outcomes in liver transplantation by enabling the clinical use of
hypothermic machine perfusion, and has been developed in
consultation with clinical and research teams specializing in liver
transplantation at Columbia University Medical Center and the
University of Chicago. The system employs a rugged, streamlined
ergonomic design for ease of use and transportability from donor
bedside to recipient operating room. For more information please
visit: http://www.organ-recovery.com/pipeline.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSFDEFMFISESE
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 6 2024 まで 7 2024
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 7 2023 まで 7 2024
